Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1956 2
1957 1
1959 2
1960 1
1961 1
1962 1
1963 2
1964 6
1965 1
1966 3
1967 4
1968 2
1969 5
1970 2
1971 3
1972 1
1973 5
1974 2
1975 8
1976 1
1977 2
1978 1
1979 1
1980 1
1982 1
1984 4
1986 3
1988 1
1989 1
1990 2
1991 2
1993 1
1994 3
1995 1
1996 6
1997 5
1998 1
1999 3
2001 1
2002 11
2003 8
2004 11
2005 8
2006 8
2007 16
2008 14
2009 15
2010 27
2011 19
2012 12
2013 15
2014 23
2015 21
2016 14
2017 13
2018 11
2019 17
2020 18
2021 18
2022 20
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

376 results
Results by year
Filters applied: . Clear all
Page 1
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Qiu X, Endress JE, Reyes J, Lim K, Font-Tello A, Syamala S, Xiao T, Reddy Chilamakuri CS, Papachristou EK, D'Santos C, Anand J, Hinohara K, Li W, McDonald TO, Luoma A, Modiste RJ, Nguyen QD, Michel B, Cejas P, Kadoch C, Jaffe JD, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K. Shu S, et al. Among authors: jovanovic b. Mol Cell. 2020 Jun 18;78(6):1096-1113.e8. doi: 10.1016/j.molcel.2020.04.027. Epub 2020 May 15. Mol Cell. 2020. PMID: 32416067 Free PMC article.
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Evens AM, et al. Among authors: jovanovic bd. J Clin Oncol. 2018 Oct 20;36(30):3015-3022. doi: 10.1200/JCO.2018.79.0139. Epub 2018 Sep 4. J Clin Oncol. 2018. PMID: 30179569 Clinical Trial.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Numan Y, et al. Among authors: jovanovic b. Am J Hematol. 2022 Mar 1;97(3):322-328. doi: 10.1002/ajh.26447. Epub 2022 Jan 7. Am J Hematol. 2022. PMID: 34981560 Clinical Trial.
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.
Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C, Stegh AH. Kumthekar P, et al. Among authors: jovanovic b. Sci Transl Med. 2021 Mar 10;13(584):eabb3945. doi: 10.1126/scitranslmed.abb3945. Sci Transl Med. 2021. PMID: 33692132 Free PMC article. Clinical Trial.
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Burt RK, et al. Among authors: jovanovic b. JAMA. 2019 Jan 15;321(2):165-174. doi: 10.1001/jama.2018.18743. JAMA. 2019. PMID: 30644983 Free PMC article. Clinical Trial.
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K. Ge JY, et al. Among authors: jovanovic b. Nat Commun. 2020 May 11;11(1):2350. doi: 10.1038/s41467-020-16170-3. Nat Commun. 2020. PMID: 32393766 Free PMC article.
[Hemorrhagic shock].
Bumbasirević V, Jovanović B, Palibrk I, Karamarković A, Radenković D, Gregorić P, Djukić V, Stevanović R, Simić D, Ivancević N. Bumbasirević V, et al. Among authors: jovanovic b. Acta Chir Iugosl. 2007;54(1):63-70. doi: 10.2298/aci0701063b. Acta Chir Iugosl. 2007. PMID: 17633864 Review. Serbian.
Batch Cultivation of Trichoderma reesei.
Jovanović B. Jovanović B. Methods Mol Biol. 2021;2234:113-118. doi: 10.1007/978-1-0716-1048-0_10. Methods Mol Biol. 2021. PMID: 33165784
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Stevens LE, Peluffo G, Qiu X, Temko D, Fassl A, Li Z, Trinh A, Seehawer M, Jovanović B, Alečković M, Wilde CM, Geck RC, Shu S, Kingston NL, Harper NW, Almendro V, Pyke AL, Egri SB, Papanastasiou M, Clement K, Zhou N, Walker S, Salas J, Park SY, Frank DA, Meissner A, Jaffe JD, Sicinski P, Toker A, Michor F, Long HW, Overmoyer BA, Polyak K. Stevens LE, et al. Among authors: jovanovic b. Cancer Res. 2023 Jan 18;83(2):264-284. doi: 10.1158/0008-5472.CAN-22-0423. Cancer Res. 2023. PMID: 36409824 Free PMC article.
376 results